# Ultragenyx Pharmaceutical Inc: Phase 3 study closed enrollment, 6 enrolled (Osteogenesis Imperfecta)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Ultragenyx Pharmaceutical Inc |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta |
| NCT ID | NCT06636071 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Osteogenesis Imperfecta |
| Intervention types | biological |
| Target enrollment | 6 |
| Site countries | Japan |
| Posted | 2024-10-10 |
| Planned start | 2024-10-25 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-28 |
| Last update posted | 2026-09-28 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06636071). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.